Portfolio company
Cadeo Oncology
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops monoclonal antibody-based immunotherapy treatments for cancer patients to induce programmed cell death in cancer cells.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Caedo Oncology
This company develops monoclonal antibody therapeutics that induce programmed cell death in cancer cells for healthcare providers and patients.
Callio Therapeutics
The company develops multi-payload antibody-drug conjugates to treat cancer patients.
cCAM Biotherapeutics
The company develops monoclonal antibody immunotherapies to treat cancer patients with advanced or recurrent malignancies.
CellmAbs
This biotech company develops monoclonal antibodies and adoptive cell therapies to treat oncology patients with solid tumours.
Cellemedy
The company develops next-generation protein therapeutics and immuno-oncology drugs for patients suffering from cancer.
Clinical stage immunotherapy company
This company develops next-generation antibody-drug conjugates to treat patients with solid tumor malignancies.
Avidicure
This biotechnology company develops multifunctional antibody therapies for cancer patients to activate immune responses while reducing toxicity.
Talix
This drug development company creates monoclonal antibodies for healthcare providers and pharmaceutical partners to treat various forms of cancer through immune-based therapies.